menu
More than 100 industry players and over 60 non-industry players currently claim to manufacture
More than 100 industry players and over 60 non-industry players currently claim to manufacture
More than 100 industry players and over 60 non-industry players currently claim to manufacture

More than 100 industry players and over 60 non-industry players currently claim to manufacture

Owing to various reasons, the demand for celltherapies is anticipated to increase over the coming years. Therefore, boththerapy developers and contract service providers may need to strengthen theircapabilities and expand available capacity. In this context, automation isexpected to be a key enabler within the cell therapy manufacturing and contractservices industry

 

To order this 550+ page report, which features160+ figures and 250+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

 

The USD 11 billion (by 2030) financial opportunitywithin the cell therapy manufacturing market has been analyzed across thefollowing segments:

§ Type of therapy

§ T-cell therapies(CAR-T therapies, TCR therapies, TIL therapies)

§ Dendritic celltherapies

§ Tumor cell therapies

§ NK cell therapies

§ Stem cell therapies

 

§ Source of cells

§ Autologous

§ Allogeneic

 

§ Scale of operation

§ Clinical

§ Commercial

 

§ Purpose ofmanufacturing

§ Contractmanufacturing

§ In-housemanufacturing

 

§ Key geographicalregions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the world

 

The Cell Therapy Manufacturing Market (3rdEdition), 2019 - 2030 report features thefollowing companies, which we identified to be key players in this domain:

§ BioNTech InnovativeManufacturing Services

§ Cell Therapies

§ Cell and Gene TherapyCatapult

§ Center for Cell andGene Therapy, Baylor College of Medicine

§ Centre for CellManufacturing Ireland, National University of Ireland

§ Clinical Cell andVaccine Production Facility, University of Pennsylvania

§ Cognate BioServices

§ FUJIFILM

§ Guy’s and St. Thomas’GMP Facility, Guy’s Hospital

§ Hitachi Chemical

§ KBI Biopharma

§ Laboratory for Celland Gene Medicine, Stanford University

§ Lonza

§ MaSTherCell

§ MEDINET

§ Molecular andCellular Therapeutics, University of Minnesota

§ Newcastle CellularTherapies Facility, Newcastle University

§ Nikon CeLL innovation

§ Rayne Cell TherapySuite, King’s College London

§ Roslin Cell Therapies

§ Scottish NationalBlood Transfusion Services Cellular Therapy Facility, Scottish Centre forRegenerative Medicine

§ Sydney Cell and GeneTherapy

§ WuXi AdvancedTherapies

 

Table of Contents

 

1. Preface

2. Executive Summary


3. Introduction

4. Market Overview

 

5. Regulatory Landscape

6. Roadmaps for Overcoming Existing Challenges

 

7. Automation Technologies for Cell TherapyManufacturing

8. Profiles: Industry Players

9. Profiles: Non-Industry Players

10. Role of Non-Profit Organizations

11. Partnerships

12. Facility Expansions

13. Capacity Analysis

 

14. Demand Analysis

 

15. Cost Price Analysis

 

16. Make Versus Buy Decision Making Framework

 

17. Market Sizing and Opportunity Analysis

 

18. Key Insights

 

19. SWOT Analysis

 

20. Conclusion

 

21. Survey Analysis

 

22. Interview Transcripts

 

23. Appendix 1: Tabulated Data

 

24. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit Cell Therapy Manufacturing Market (3rdEdition), 2019 - 2030

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com